The multiple-logistic regression analyses determined that the most consistent predictors for negative clinical outcomes in months 12 to 48 were relapses during months 0 to 12 and EDSS scores at baseline and months 0 to 12.
This retrospective cohort study sought to assess the outcomes for individuals with multiple sclerosis who transitioned from natalizumab to dimethyl fumarate.
The VELOCE trial (ClinicalTrials.gov Identifier: NCT02545868) was an open-label, randomized, phase 3b study designed to assess whether ocrelizumab could raise the humoral responses to vaccines in individuals with relapsing multiple sclerosis.
Investigators sought to determine the association between smoking and headache.
A prospective, blinded, randomized trial comparing once-weekly and twice-weekly IM IFNβ-1a may be indicated.
Medication overuse headache may be a significant disease burden in the general population.
Investigators collected audio recording of physician-patient interaction during office visits to evaluate communication patterns.
Investigators note that tailored behavioral and physical interventions may be beneficial for the patient’s individual need.
Investigators examined whether post-void residual volumes were linked to urinary symptoms in patients with multiple sclerosis.
A study evaluated the long-term adverse effects of maternal depression on child development.
